Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines

Impacto

Downloads

Downloads per month over past year

Luczkowiak, Joanna and Rivas, Gonzalo and Labiod, Nuria and Lasala, Fátima and Rolo, Marta and Lora-Tamayo Morillo-Velarde, Jaime and Mancheno Losa, Mikel and Rial Crestelo, David and Pérez Rivilla, Alfredo and Folgueira López, María Dolores and Delgado Vázquez, Rafael (2023) Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines. Journal of Medical Virology, 95 (1). ISSN 0146-6615

[thumbnail of Journal of Medical Virology - 2022 - Luczkowiak - Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated.pdf]
Preview
PDF
Creative Commons Attribution Non-commercial No Derivatives.

788kB

Official URL: https://doi.org/10.1002/jmv.28268



Abstract

We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID-19 naïve and convalescent individuals. Third doses of mRNA COVID-19 vaccines induced a significant increase in potency and breadth of neutralization against SARS-CoV-2 variants of concern (VoC) including Omicron subvariants BA.1, BA.2, and BA.2.12.1, that were cross-neutralized at comparable levels and less for BA.4/5. This booster effect was especially important in naïve individuals that only after the third dose achieved a level that was comparable with that of vaccinated COVID-19 convalescents except for BA.4/5. Avidity of RBD-binding antibodies was also significantly increased in naïve individuals after the third dose, indicating an association between affinity maturation and cross neutralization of VoC. These results suggest that at least three antigenic stimuli by infection or vaccination with ancestral SARS-CoV-2 sequences are required to induce high avidity cross-neutralizing antibodies. Nevertheless, the circulation of new subvariants such as BA.4/5 with partial resistance to neutralization will have to be closely monitored and eventually consider for future vaccine developments.


Item Type:Article
Additional Information:

CRUE-CSIC (Acuerdos Transformativos 2022)

Uncontrolled Keywords:avidity, COVID‐19, neutralizing antibodies, Omicron, SARS‐CoV‐2, vaccines, variants of concern
Subjects:Medical sciences > Medicine > Immunology
ID Code:75687
Deposited On:21 Nov 2022 12:23
Last Modified:21 Nov 2022 14:52

Origin of downloads

Repository Staff Only: item control page